Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Switch or Sequential Combination Therapy of Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Low HBsAg and HBeAg Titers After Long-term Entecavir Therapy: A Multicenter, Prospective Cohort Study

NCT02589652 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT02589652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02589652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Switch or Sequential Combination Therapy of Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Low HBsAg and HBeAg Titers After Long-term Entecavir Therapy: A Multicenter, Prospective Cohort Study
Lead sponsor
Huashan Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2015
Completion date
October 31, 2017
Enrollment
294 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b